MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes. - Wikidata - awgldk - TriplyDB

MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes.

MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes.

http://www.wikidata.org/entity/Q37661175

about

Integrated analysis of competing endogenous RNA network revealing lncRNAs as potential prognostic biomarkers in human lung squamous cell carcinoma mTOR signaling-related MicroRNAs and Cancer involvement.

P2860

Q42371601-4F2918E9-D17B-4022-A0F9-9C31131A08CC Q55069878-F87448BE-FA81-4384-96B4-1652F9E86D76

P2860

MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes.

http://www.wikidata.org/entity/Q37661175

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 February 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

MicroRNA-Related Polymorphisms ...... ung Cancer Treatment Outcomes.

@en

MicroRNA-Related Polymorphisms ...... ung Cancer Treatment Outcomes.

@nl

type

label

MicroRNA-Related Polymorphisms ...... ung Cancer Treatment Outcomes.

@en

MicroRNA-Related Polymorphisms ...... ung Cancer Treatment Outcomes.

@nl

prefLabel

MicroRNA-Related Polymorphisms ...... ung Cancer Treatment Outcomes.

@en

MicroRNA-Related Polymorphisms ...... ung Cancer Treatment Outcomes.

@nl

P1433

Q37661175-794B829C-20B4-495B-8BB0-D3CE8A4C2D14

P1476

Q37661175-83743E0D-D01D-4A5A-8439-AAD7D8F70B3A

P2093

Q37661175-3012C68D-F8A7-4590-89FA-399A9A4ECDD9

Q37661175-4E8DADB0-C56D-47DE-AAA6-2EB567AE9D93

Q37661175-590FA49A-F760-49BE-93CB-58DFD1BF8849

Q37661175-5EAD73C3-397B-4353-9B26-810B15F923CD

Q37661175-7F82AE8E-493C-43F4-9CB9-16543AEFBE01

Q37661175-C3AD8D78-BD62-4E0B-A8F0-7E4B1DCBA8C8

Q37661175-DCBC2B29-03E1-46CA-B218-0AF3D5A00301

P2860

Q37661175-12F561D4-05A2-4685-B67E-33459160ACEB

Q37661175-145959AD-64B4-4D3C-B464-B8CE5F974D39

Q37661175-151D74CF-4BA2-4093-AD8C-49ECCF2ED185

Q37661175-1A54F506-1981-4CED-BD5A-535D7C1E1D71

Q37661175-2186B8E0-7A10-4602-BA54-5B9A7CED8DFF

Q37661175-23A68A86-08E1-4E3E-9B0C-5B6295632210

Q37661175-261FB8FE-FB9B-475D-AE2D-F807828646FE

Q37661175-29F0E4B3-CE22-4927-8CB9-EE540B1D700A

Q37661175-34221379-9A81-4C69-A6B3-4CFF5E37952F

Q37661175-3449D6B1-EB72-470E-9077-277B69BB5D26

P304

Q37661175-B3BE2D5E-E5E4-4220-8945-90CB71E87A10

P31

Q37661175-DC56D38F-EEDC-4265-83E7-FF241830F819

P356

Q37661175-A782E853-2196-41B4-B651-C3C923C0323A

P407

Q37661175-4BF036C6-0932-42B4-BA8A-FB78EF1F2A88

P478

Q37661175-8AC875A9-E599-40E8-BD50-A93011FC4960

P50

Q37661175-37CE7F38-908B-4B20-BB7B-2B2BD02864BF

Q37661175-410D29D9-7DCA-45C6-8950-32738ADB26E2

Q37661175-97B7983D-758B-466E-AC8F-C306884B719A

Q37661175-9AFF55B4-2211-42EC-B4EA-9AF1BFB0B1A8

P577

Q37661175-5F4ECAC4-41F9-4CE4-AC25-8757994167D5

P698

Q37661175-86AFC7B4-97A7-4249-95B5-293C66587E0D

P921

Q37661175-D76EF7AD-6E6F-4495-B6CB-A7EAAF60336F

P932

Q37661175-32DED413-7403-4EF2-857C-CFB60C37BC3E

P356

P1433

BioMed Research International

P1476

MicroRNA-Related Polymorphisms ...... Lung Cancer Treatment Outcomes

@en

P2093

Jingbo Wang

http://www.w3.org/2001/XMLSchema#string

Jun Liang

http://www.w3.org/2001/XMLSchema#string

Lihong Wu

http://www.w3.org/2001/XMLSchema#string

Lipin Liu

http://www.w3.org/2001/XMLSchema#string

Wenjue Zhang

http://www.w3.org/2001/XMLSchema#string

Yu Men

http://www.w3.org/2001/XMLSchema#string

Zongmei Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial.

Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients

Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.

PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy

Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival.

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

Polymorphisms in the mTOR gene and risk of sporadic prostate cancer in an Eastern Chinese population.

P304

6501385

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2017/6501385

http://www.w3.org/2001/XMLSchema#string

P407

P478

2017

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28280736

http://www.w3.org/2001/XMLSchema#string

P921

P932

5322445

http://www.w3.org/2001/XMLSchema#string